Ovarian Cancer Clinical Trials in Tennessee

Showing 181-200 of 253 trials

Clinical Trial of Lurbinectedin (PM01183) in Platinum Resistant Ovarian Cancer Patients

NCT02421588

Multicenter, open-label, randomized, controlled phase III clinical trial to evaluate the activity and safety of PM01183 versus PLD or topotecan as control arm in patients with platinum-resistant ovarian cancer. PM01183 will be explored as single agent in the experimental arm (Arm A) versus PLD or topotecan in the control arm (Arm B).

Ovarian Cancer

PharmaMar442 participantsStarted May 2015

Peoria, Arizona, United States • Greenbrae, California, United States • La Jolla, California, United States +25 more locations

COMPLETEDPhase 1/229 miles

A Study LY2228820 for Recurrent Ovarian Cancer

NCT01663857

A study for women with ovarian cancer that has returned at least 6 months after platinum-based chemotherapy.

Epithelial Ovarian CancerFallopian Tube CancerPrimary Peritoneal Cancer

Eli Lilly and Company118 participantsStarted Jul 2012

Phoenix, Arizona, United States • Tucson, Arizona, United States • Sarasota, Florida, United States +27 more locations

Clinical Trial of Lurbinectedin (PM01183) in Platinum Resistant Ovarian Cancer Patients

A Study LY2228820 for Recurrent Ovarian Cancer

Ovarian Cancer Trials in Other Cities

Study of SC-003 Alone and in Combination With ABBV-181 in Subjects With Platinum-Resistant/Refractory Ovarian Cancer

ILX-295501 in Treating Patients With Stage III or Stage IV Ovarian Cancer That Has Not Responded to Previous Treatment

Quality of Life and Care Needs of Patients With Persistent or Recurrent Ovarian Cancer, Fallopian Tube Cancer, or Peritoneal Cancer

VTX-2337 and Pegylated Liposomal Doxorubicin (PLD) in Patients With Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer

Temsirolimus and Bevacizumab in Treating Patients With Advanced Endometrial, Ovarian, Liver, Carcinoid, or Islet Cell Cancer

Temsirolimus, Carboplatin, and Paclitaxel as First-Line Therapy in Treating Patients With Newly Diagnosed Stage III-IV Clear Cell Ovarian Cancer

Study of Talazoparib, a PARP Inhibitor, in Patients With Advanced or Recurrent Solid Tumors

Phase 1b Safety Study of CMB305 in Patients With Locally Advanced, Relapsed, or Metastatic Cancer Expressing NY-ESO-1

A Trial of ABT-888 in Combination With Temozolomide Versus Pegylated Liposomal Doxorubicin Alone in Ovarian Cancer

Study of Ramucirumab in Ovarian Cancer

A Study of Chemotherapy Treatment for Patients With Ovarian Cancer

hTERT Immunotherapy Alone or in Combination With IL-12 DNA Followed by Electroporation in Adults With Solid Tumors at High Risk of Relapse

A Study Evaluating MM-310 in Patients With Solid Tumors

Why do Oral Contraceptives Prevent Ovarian Cancer?

Open Label, Multi-center Study to Assess the Safety, Tolerability and Pharmacokinetics of CUDC-907 in Subjects With Advanced/Relapsed Solid Tumors

Acalabrutinib (ACP-196) Alone and in Combination With Pembrolizumab in Ovarian Cancer (KEYNOTE191)

A Trial Using Novel Markers to Predict Malignancy in Elevated-Risk Women

Pharmacokinetic Study of Avastin and Doxil in Ovarian Cancer

Other Conditions in Tennessee